Prøve GULL - Gratis

Union Budget 2025 targets healthcare, medical education & Al, omitting medical devices.

Bio Spectrum

|

March 2025

The overall macro-economic and policy direction measures announced in the Union Budget 2025, particularly focusing on cancer care, medical education, AI, R&D and innovation, is appreciable. There are many key points in the budget announcements that will strengthen the economy and propel the GDP growth. However, without any mention of investment promotion measures for the 70 per cent imports-dependent medical devices sector in the budget speech, industry disappointment was an expected reaction. Let's delve further.

- Dr Manbeena Chawla

Union Budget 2025 targets healthcare, medical education & Al, omitting medical devices.

Union Minister of Finance and Corporate Affairs Nirmala Sitharaman presented the Union Budget 2025-26 in Parliament on February 1, 2025. While multiple new initiatives within the healthcare sector were announced such as the establishment of new Day Care Cancer Centres in district hospitals; Full exemption from Basic Customs Duty of 36 lifesaving drugs and medicines for treating cancer, rare diseases and chronic diseases; addition of 10,000 seats in medical colleges and hospitals next year; Announcement of National Manufacturing Mission; Promotion of medical tourism etc., expectations of the Medical Devices sector have not been met.

The Indian Medical Devices Industry was expecting an increase in Custom Duty to a nominal 10 per cent to 15 per cent (and as a Predictable Tariff Policy); Correction of Inverted Duty by levying Health Cess of 5 per cent custom duty on balance Medical Devices; Trade Margin Capping by monitoring MRP of Imports; Income Tax benefits for CAPEX and R&D investments in Medical Devices. The industry was also hoping that the government could consider standardising the GST rate of 12 per cent across all medical devices as it would simplify the tax structure, ensuring consistency and ease of doing business.

image“The industry is disappointed that expectations of the Medical Devices sector and many of which had been supported by the Department of Pharmaceutical too as an investment enabler under the National Medical Device 2023 policy finds no mention in the budget speech. We were hoping to see the Finance Minister speak about Medical Devices as Make in India enabler and address the 70 per cent import dependence due to inadequate tariff protection with duties at zero to 7.5 per cent in most cases and an ever-rising imports bill that is expected to cross Rs 75,000 crore this year”, said

FLERE HISTORIER FRA Bio Spectrum

Bio Spectrum

Bio Spectrum

WHO certifies Suriname malaria-free

Suriname became the first country in the Amazon region to receive malaria-free certification from the World Health Organization (WHO).

time to read

1 min

August 2025

Bio Spectrum

Bio Spectrum

Torrent Pharma buys controlling stake in JB Pharma from KKR for Rs 25,689 Cr valuation

Ahmedabad-based Torrent Pharmaceuticals and global investment firm KKR have announced that Torrent has entered into definitive agreements to acquire controlling stake in Mumbai-based J. B. Chemicals and Pharmaceuticals (JB Pharma) from KKR at an Equity Valuation of Rs 25,689 crore (on fully diluted basis), followed by a merger of the two entities.

time to read

1 min

August 2025

Bio Spectrum

Suraksha Diagnostics injects Rs 22 Cr to establish Eastern India's largest genomics lab

Suraksha Diagnostics, one of the leading diagnostics chains in Eastern India, has launched one of the largest and a state-of-theart genomics lab in Eastern India.

time to read

1 min

August 2025

Bio Spectrum

Illumina buys SomaLogic for $425 M to accelerate proteomics business

Illumina, Inc. has entered into a definitive agreement with Standard BioTools under which Illumina will acquire SomaLogic, a leader in data-driven proteomics technology, and other specified assets for $350 million in cash payable at closing, subject to customary adjustments, plus up to $75 million in near-term performance-based milestones and performance-based royalties.

time to read

1 min

August 2025

Bio Spectrum

Bio Spectrum

Kashmik Formulation to expand capacity, eyes Rs 100 Cr revenue in FY26

Kashmik Formulation, a pharmaceutical manufacturing company headquartered in Ahmedabad, has announced significant expansion plans aimed at increasing production capacity, strengthening its presence in international markets, and enhancing operational efficiencies through automation.

time to read

1 min

August 2025

Bio Spectrum

WHO highlights risks associated with use of semaglutide medicines

The World Health Organisation (WHO) is alerting healthcare professionals and regulatory authorities to the risk of non-arteritic anterior ischemic optic neuropathy (NAION) associated with the use of semaglutide medicinesOzempic, Rybelsus, and Wegovy.

time to read

1 min

August 2025

Bio Spectrum

Bio Spectrum

Lamark Biotech secures Rs 6.5 Cr to accelerate development of thermostable insulin

Lamark Biotech, an innovation-led biopharma startup, has raised Rs 6.5 crore in a PreSeries A round led by IAN Group, including IAN Alpha Fund, powered by BioAngels, Dr Vinayender Tulla, Dr Nita Roy, and Venkataraman KNK, domain experts of IAN's angel investors led the round.

time to read

1 min

August 2025

Bio Spectrum

Bio Spectrum

AstraZeneca invests Rs 166 Cr to expand Global Hub in Bengaluru

AstraZeneca, a global, science-led biopharmaceutical company, has announced the expansion of its state-of-the-art Global Hub in Bengaluru, strengthening its presence in India.

time to read

1 min

August 2025

Bio Spectrum

Bio Spectrum

Novo Nordisk launches injectable Semaglutide for weight management in India

Novo Nordisk, a leading global healthcare company headquartered in Denmark with over a 100-year legacy of chronic disease care, has announced the launch of Wegovy (injectable Semaglutide) in India.

time to read

1 min

August 2025

Bio Spectrum

Bio Spectrum

Can Policy Reforms & Investments Trigger India's MedTech MAKEOVER?

India's MedTech sector has long been import-dependent. The Centre is now working to change this by positioning the country as an export-oriented manufacturing hub. A series of policies and investments have been introduced to support this shift. Have these made an impact? What steps are necessary to strengthen India's position in the global medical technology (MedTech) landscape? Let's find out.

time to read

12 mins

August 2025

Listen

Translate

Share

-
+

Change font size